Abstract: The present invention relates to a topical composition containing a probiotic and hyaluronic acid or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of inflammatory bowel disease.

Abstract: In the present invention, a new combination is disclosed comprising (i) 5-aminosalicylic acid (5-ASA) or a derivative thereof, or a pharmacologically acceptable salt thereof, and (ii) a group D vitamin, a derivative thereof, a metabolite or analogue, for use in the prevention and/or treatment of colorectal cancer (CRC). A further aspect of the invention is directed to pharmaceutical compositions comprising said combination together with at least one physiologically acceptable excipient and the use thereof in the prevention and/or in the treatment of the colorectal cancer.

Abstract: In the present invention, a new combination is disclosed comprising (i) 5-aminosalicylic acid (5-ASA) or a derivative thereof, or a pharmacologically acceptable salt thereof, and (ii) a group D vitamin, a derivative thereof, a metabolite or analogue, for use in the prevention and/or treatment of colorectal cancer (CRC). A further aspect of the invention is directed to pharmaceutical compositions comprising said combination together with at least one physiologically acceptable excipient and the use thereof in the prevention and/or in the treatment of the colorectal cancer.

Abstract: The present invention refers to pharmaceutical beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and to their oral use in the treatment of inflammatory pathologies of the intestinal tract. Said compositions in microspheres comprise: a) a core consisting of a microsphere of inert material; b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient; c) a second modified-release gastro-resistant coating. The present invention also refers to a process for obtaining said compositions.

Abstract: The present invention refers to the compounds corresponding to the following general formulas (I) and (Ia): wherein: R?C4-C8 alkanoyl; and X?NH—R1 where R1?H, or an amine protecting group; and/or the pharmaceutically acceptable salts thereof. A further object of the present invention is represented by the use of the compounds of formula (Ia), in particular 5-amino-2-(butyryloxy)benzoic acid and/or pharmaceutically acceptable salts thereof, as a medicament and by the use thereof for the treatment of intestinal inflammatory diseases.

Abstract: The present invention refers to controlled release granular compositions of mesalazine and their use in the treatment of inflammatory pathologies of the intestinal tract. The aforesaid granular compositions comprise: a) a central core comprising an inert substrate; b) an intermediate layer comprising mesalazine and one or more physiologically acceptable excipients; c) a gastro-resistant coating. The present invention then refers to a process for obtaining the aforesaid granular compositions.

Abstract: A method is disclosed for the determination of 5-ASA efficacy in preventing and/or treating CRC in a mammalian, which comprises the analysis of the inhibition of the ?-catenin pathway in presence of 5-ASA. More in details, the method comprises measuring the expression of at least one gene involved in the regulation of the ?-catenin signalling pathway, such as ?-protocadherin, E-cadherin, ?-catenin, Axin1, ICAT, p21waf?1 and the expression of onco-suppressor genes, such as KLF4 and CEBP?. Gene expression can be measured in accordance to the methods commonly available in the art such as QRT-PCR and immunohistochemistry.

Abstract: The present invention refers to pharmaceutical beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and to their oral use in the treatment of inflammatory pathologies of the intestinal tract. Said compositions in microspheres comprise: a) a core consisting of a microsphere of inert material; b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient; c) a second modified-release gastro-resistant coating. The present invention also refers to a process for obtaining said compositions.

Abstract: The present invention refers to the compounds corresponding to the following general formula (I): wherein: R?C4-C8 alkanoyl; and X?NH—R1 where R1?H, or an amine protecting group; and/or the pharmaceutically acceptable salts thereof. Preferred compounds according to the present invention are represented by the following formula (Ia): wherein: R?C4-C8 alkanoyl; and/or the pharmaceutically acceptable salts thereof. In a preferred embodiment, an object of the present invention is to provide 5-amino-2-(butyryloxy)benzoic acid and/or the pharmaceutically acceptable salts thereof, preferably hydrochloride salt. A further object of the present invention is represented by the use of the compounds of formula (Ia), in particular 5-amino-2-(butyryloxy)benzoic acid and/or pharmaceutically acceptable salts thereof, as a medicament and by the use thereof for the treatment of intestinal inflammatory diseases.

Abstract: A robotized surgery system (10) comprises at least one robot arm (11) which acts under the control of a control console (12) intended for the surgeon. The console (12) comprises an eye tracking system (21) for detecting the direction of the surgeon's gaze and for entering commands depending on the directions of the gaze detected. The console (22) comprises advantageously a screen (23) with at least one zone (23) for viewing the operating field and, among the commands which can be performed depending on the gaze directions, there is advantageously an automatic command for enabling or disabling the movement of the robot arm (11) when a gaze direction which falls within or outside of said zone (23) of the screen is detected.

Abstract: The present invention refers to controlled release granular compositions of mesalazine and their use in the treatment of inflammatory pathologies of the intestinal tract. The aforesaid granular compositions comprise: a) a central core comprising an inert substrate; b) an intermediate layer comprising mesalazine and one or more physiologically acceptable excipients; c) a gastro-resistant coating. The present invention then refers to a process for obtaining the aforesaid granular compositions.

Abstract: A method is disclosed for the determination of 5-ASA efficacy in preventing and/or treating CRC in a mammalian, which comprises the analysis of the inhibition of the ?-catenin pathway in presence of 5-ASA. More in details, the method comprises measuring the expression of at least one gene involved in the regulation of the ?-catenin signalling pathway, such as ?-protocadherin, E-cadherin, ?-catenin, Axin1, ICAT, p21waf-1 and the expression of onco-suppressor genes, such as KLF4 and CEBP?. Gene expression can be measured in accordance to the methods commonly available in the art such as QRT-PCR and immunohistochemistry.

Abstract: A one-way valve for a container supplying a liquid under pressure when the container is compressed is designed to be inserted between an outlet of the container and the end of a supply nozzle connected to the container. The valve includes a hollow body inserted partially into the outlet of the container. A base of the hollow body, which is engaged by the end of the nozzle, is open, while the other base of the body has an essentially central hole through which the liquid passes. The hollow body accommodates internally an obturator member essentially including a shaped stopper connected, via elastically deformable lugs, to a support element. The support element has a longitudinal passage of a cross-sectional area greater than that of a cavity formed in the stopper. The lugs are designed to keep the stopper within the hole of the hollow body when the container is not compressed and to allow it to be moved out of the hole when the container is compressed in order to supply the liquid.